“Our review of strategic options continues, as we strive to maximize value for our stockholders,” said Mel Sorensen, M.D., Galera’s President and CEO. “Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path for avasopasem. The process could ultimately culminate in the dissolution of the Company.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTX:
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
- Galera Therapeutics Enacts Plan to Deter Hostile Takeovers
- Galera Therapeutics adopts limited duration stockholder rights agreement
- Galera Adopts Limited Duration Stockholder Rights Agreement
- Biotech Alert: Searches spiking for these stocks today